These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 26143385)

  • 1. The promise of treatment as prevention for hepatitis C: Meeting the needs of people who inject drugs?
    Harris M; Albers E; Swan T
    Int J Drug Policy; 2015 Oct; 26(10):963-9. PubMed ID: 26143385
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluating the population impact of hepatitis C direct acting antiviral treatment as prevention for people who inject drugs (EPIToPe) - a natural experiment (protocol).
    Hickman M; Dillon JF; Elliott L; De Angelis D; Vickerman P; Foster G; Donnan P; Eriksen A; Flowers P; Goldberg D; Hollingworth W; Ijaz S; Liddell D; Mandal S; Martin N; Beer LJZ; Drysdale K; Fraser H; Glass R; Graham L; Gunson RN; Hamilton E; Harris H; Harris M; Harris R; Heinsbroek E; Hope V; Horwood J; Inglis SK; Innes H; Lane A; Meadows J; McAuley A; Metcalfe C; Migchelsen S; Murray A; Myring G; Palmateer NE; Presanis A; Radley A; Ramsay M; Samartsidis P; Simmons R; Sinka K; Vojt G; Ward Z; Whiteley D; Yeung A; Hutchinson SJ
    BMJ Open; 2019 Sep; 9(9):e029538. PubMed ID: 31551376
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Research priorities to achieve universal access to hepatitis C prevention, management and direct-acting antiviral treatment among people who inject drugs.
    Grebely J; Bruneau J; Lazarus JV; Dalgard O; Bruggmann P; Treloar C; Hickman M; Hellard M; Roberts T; Crooks L; Midgard H; Larney S; Degenhardt L; Alho H; Byrne J; Dillon JF; Feld JJ; Foster G; Goldberg D; Lloyd AR; Reimer J; Robaeys G; Torrens M; Wright N; Maremmani I; Norton BL; Litwin AH; Dore GJ;
    Int J Drug Policy; 2017 Sep; 47():51-60. PubMed ID: 28683982
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Priorities and recommended actions for how researchers, practitioners, policy makers, and the affected community can work together to improve access to hepatitis C care for people who use drugs.
    Day E; Broder T; Bruneau J; Cruse S; Dickie M; Fish S; Grillon C; Luhmann N; Mason K; McLean E; Trooskin S; Treloar C; Grebely J
    Int J Drug Policy; 2019 Apr; 66():87-93. PubMed ID: 30743093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is hepatitis C virus elimination possible among people living with HIV and what will it take to achieve it?
    Martin NK; Boerekamps A; Hill AM; Rijnders BJA
    J Int AIDS Soc; 2018 Apr; 21 Suppl 2(Suppl Suppl 2):e25062. PubMed ID: 29633560
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevention, treatment and care of hepatitis C virus infection among people who inject drugs.
    Bruggmann P; Grebely J
    Int J Drug Policy; 2015 Feb; 26 Suppl 1():S22-6. PubMed ID: 25245939
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment advocate tactics to expand access to antiviral therapy for HIV and viral hepatitis C in low- to high-income settings: making sure no one is left behind.
    Grillon C; Krishtel PR; Mellouk O; Basenko A; Freeman J; Mendão L; Andrieux-Meyer I; Morin S
    J Int AIDS Soc; 2018 Apr; 21 Suppl 2(Suppl Suppl 2):e25060. PubMed ID: 29633580
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Are Interferon-Free Direct-Acting Antivirals for the Treatment of HCV Enough to Control the Epidemic among People Who Inject Drugs?
    Lima VD; Rozada I; Grebely J; Hull M; Lourenco L; Nosyk B; Krajden M; Yoshida E; Wood E; Montaner JS
    PLoS One; 2015; 10(12):e0143836. PubMed ID: 26633652
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The civil society monitoring of hepatitis C response related to the WHO 2030 elimination goals in 35 European countries.
    Maticic M; Pirnat Z; Leicht A; Zimmermann R; Windelinck T; Jauffret-Roustide M; Duffell E; Tammi T; Schatz E
    Harm Reduct J; 2020 Nov; 17(1):89. PubMed ID: 33213481
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modeling Combination Hepatitis C Virus Treatment and Prevention Strategies in a Network of People Who Inject Drugs in the United States.
    Zelenev A; Li J; Shea P; Hecht R; Altice FL
    Clin Infect Dis; 2021 Mar; 72(5):755-763. PubMed ID: 32060534
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modelling the elimination of hepatitis C as a public health threat in Iceland: A goal attainable by 2020.
    Scott N; Ólafsson S; Gottfreðsson M; Tyrfingsson T; Rúnarsdóttir V; Hansdottir I; Hernandez UB; Sigmundsdóttir G; Hellard M
    J Hepatol; 2018 May; 68(5):932-939. PubMed ID: 29274408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence-based and guideline-concurrent responses to narratives deferring HCV treatment among people who inject drugs.
    Childs E; Assoumou SA; Biello KB; Biancarelli DL; Drainoni ML; Edeza A; Salhaney P; Mimiaga MJ; Bazzi AR
    Harm Reduct J; 2019 Feb; 16(1):14. PubMed ID: 30744628
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Barriers to access to hepatitis C treatment with direct-acting antivirals in people who inject drugs in the community setting.
    Yela E; Solé N; Puig L; López Gallegos D; Clua-García R
    Harm Reduct J; 2024 Apr; 21(1):88. PubMed ID: 38678266
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elimination of hepatitis C virus infection among people who use drugs: Ensuring equitable access to prevention, treatment, and care for all.
    Grebely J; Hajarizadeh B; Lazarus JV; Bruneau J; Treloar C;
    Int J Drug Policy; 2019 Oct; 72():1-10. PubMed ID: 31345644
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The need for treatment scale-up to impact HCV transmission in people who inject drugs in Montréal, Canada: a modelling study.
    Cousien A; Leclerc P; Morissette C; Bruneau J; Roy É; Tran VC; Yazdanpanah Y; Cox J
    BMC Infect Dis; 2017 Feb; 17(1):162. PubMed ID: 28222681
    [TBL] [Abstract][Full Text] [Related]  

  • 16. "Everybody living with a chronic disease is entitled to be cured": Challenges and opportunities in scaling up access to direct-acting antiviral hepatitis C virus treatment among people who inject drugs.
    Goodyear T; Ti L; Carrieri P; Small W; Knight R
    Int J Drug Policy; 2020 Jul; 81():102766. PubMed ID: 32416525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Barriers and facilitators of HIV and hepatitis C care among people who inject drugs in Nairobi, Kenya: a qualitative study with peer educators.
    Ludwig-Barron NT; Guthrie BL; Mbogo L; Bukusi D; Sinkele W; Gitau E; Farquhar C; Monroe-Wise A
    Harm Reduct J; 2021 Dec; 18(1):133. PubMed ID: 34922548
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness and cost-effectiveness of interventions targeting harm reduction and chronic hepatitis C cascade of care in people who inject drugs: The case of France.
    Cousien A; Tran VC; Deuffic-Burban S; Jauffret-Roustide M; Mabileau G; Dhersin JS; Yazdanpanah Y
    J Viral Hepat; 2018 Oct; 25(10):1197-1207. PubMed ID: 29660211
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eligibility of persons who inject drugs for treatment of hepatitis C virus infection.
    Arain A; Robaeys G
    World J Gastroenterol; 2014 Sep; 20(36):12722-33. PubMed ID: 25278674
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interventions to prevent HIV and Hepatitis C in people who inject drugs: a review of reviews to assess evidence of effectiveness.
    MacArthur GJ; van Velzen E; Palmateer N; Kimber J; Pharris A; Hope V; Taylor A; Roy K; Aspinall E; Goldberg D; Rhodes T; Hedrich D; Salminen M; Hickman M; Hutchinson SJ
    Int J Drug Policy; 2014 Jan; 25(1):34-52. PubMed ID: 23973009
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.